ImmuNext develops immunomodulatory compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Negative checkpoint regulators are changing the way cancer is treated. Our flagship product, anti-VISTA, is partnered with Johnson & Johnson. We believe that our next product, VISTA-Ig, will establish a new class of compounds for autoimmunity. Our third product is a breakthrough antibody that targets CD40L, the 'holy grail' of autoimmune treatment. Our core competencies are discovery, target biology and pre-clinical drug development.
Due to the volume of applicants, we will only respond directly to candidates whose backgrounds most closely align with the requirements of the position.